#EULAR2022 OP0277 MSK IRAE from Checkpoint inhibitors ⭐️118 pts w MSK complaints 76% w arthralgias/myalgias, 30% with inflammatory rheumatic features Most grade 1/2, 2 grade 4 (myositis) 23 (19.5%) required d/c, time of resolution ~3 mos, 20% persistence at end of study @RheumNow https://t.co/SINqmmjsLq